Acceptable toxicity profile is seen with relugolix in advanced prostate cancer
“Relugolix, an oral nonpeptide GnRH receptor antagonist, was generally well tolerated in the phase 3 HERO study,” wrote Bryan Mehlhaff, MD, and coauthors.
“Relugolix, an oral nonpeptide GnRH receptor antagonist, was generally well tolerated in the phase 3 HERO study,” wrote Bryan Mehlhaff, MD, and coauthors.
“This data should bolster physicians’ confidence in recommending active surveillance for their patients when it is an appropriate option,” says Timothy J. Daskivich, MD.
“Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
The AssureMDx test demonstrated an area under the curve of 0.80 in detecting urinary tract recurrences in MIBC.
“As most of us know, 1 in 8 couples undergo issues pertaining to fertility, and in about half of those cases, there is a male…
“These results are encouraging and suggest that circulating biomarkers may be useful in guiding the use of radium-223 therapy,” says David T. Miyamoto, MD, PhD.
“We must do more to help surgeons prepare for the impact of adverse events before they happen,” says Kevin Turner MA DM FRCS(Urol).
In the intervention group, the HRQOL score changed by 23.9 points between baseline and week 13, from 18.4 to 29.5.
Comprehensive insights on ARPIs (androgen receptor pathway inhibitors) for the treatment of prostate cancer, highlighting what influences treatment decisions and safety profiles of the available…
Overall, participating pathologists felt that there is potential to increase diagnostic efficiency by using Galen Prostate in a clinical setting.